Revised SPC: Soliris (eculizumab) 300mg concentrate for solution for infusion

Section 4.2 gives more specific duration for infusion, and section 4.5 warns of interaction with iv immunoglobulin which may result in reduced eculizumab effectiveness. When immunosuppressant therapy is decreased patients should be monitored for signs and symptoms of relapse.


electronic Medicines compendium